Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Melanoma 1Lymphoma, Non-Hodgkin 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 90Vincristine 83Doxorubicin 69Prednisone 66Cytarabine 59Methotrexate 58Rituximab 49Etoposide 43Radiotherapy 41Dexamethasone 41Filgrastim 39Leucovorin 27Mercaptopurine 26Granulocyte Colony-Stimulating Factor 26pegaspargase 22Calcium Dobesilate 22Daunorubicin 21Asparaginase 20merphos 19Specimen Handling 18Thioguanine 17Hydrocortisone 16Bleomycin 16Peripheral Blood Stem Cell Transplantation 14Vinblastine 13Gene Expression Profiling 13Methylprednisolone 12Ifosfamide 12Gemcitabine 12dexamethasone acetate 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Bone Density × Lymphoid × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡